Lars H Lindner

Oncology — LMU Klinikum, Germany

LeadR Profile

Lars H Lindner LMU Klinikum Germany
826 ScienceLeadR Reputation 826
Network Map

Oncology

Subspecialties: Surgery - Medical Imaging - Histology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026

Source: PubMed

Ludwig-Maximilians-Universität München

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 237

Citations

Citations: 6 880 1st author: 20 Last author: 42 Unique author: 8


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Variations in surgical strategies and treatment allocation for retroperitoneal sarcomas across German-speaking sarcoma centres.
multiple chronic conditions, sarcoma, histology, therapeutics
Eur J Surg Oncol20260
Prognostic Factors and Survival Outcomes in Resectable Thoracic Soft Tissue and Bone Sarcomas.
neoplasms, sarcoma, therapeutics, tissues, prognosis
Cancers (Basel)20261
Stereotactic heart ablative radiotherapy (SHARP): a prospective multicentric phase II trial.
radiotherapy, heart, neoplasms, therapeutics
Strahlenther Onkol20260
Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study.
cohort studies, machine learning, sarcoma, histology, therapeutics, learning, tissues
Oncol Ther20260
Response to Letter to the Editor: Comments on "Surgery for Retroperitoneal Soft Tissue is Safe following Multimodal Treatment with Regional Hyperthermia".
hyperthermia, combined modality therapy, therapeutics, tissues
Ann Surg Oncol20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7
Phase 2 3
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 6
Unknown 3
Recruiting 2
Active not recruiting 1

By type:

Interventional 12

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 2
multicentricup10 7

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Public Title Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First line Treatment in Participants with Metastatic Leiomyosarcoma
2022-502975-45-00 — leiomyosarcoma, doxorubicin, therapeutics
Phase 3Active not recruiting2023
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00 — sarcoma, ewing, maintenance, sarcoma, therapeutics
Phase 3Recruiting2022
tTF NGR Randomized Study STS
NCT05597917 — safety, saline solution, aminopeptidases, neoplasms, disease progression, drug therapy, contraindications, sarcoma, trabectedin, therapeutics, tissues, cd13 antigens, chemotherapy
Phase 3Recruiting2021

LeadR Networks

Main global connection map